|Articles|August 1, 2019
- Pharmaceutical Executive-08-01-2019
- Volume 39
- Issue 8
Pharmaceutical Executive, August 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive August 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 7 years ago
A Look Back & Forward on Innovationalmost 7 years ago
Routes to Exclusivity in Cell-Based Therapy Developmentalmost 7 years ago
Gene Therapy: Managing the Clinical Trial Minefieldsalmost 7 years ago
The Call to Cure: Geoff MacKay, AVROBIOalmost 7 years ago
Four Takeaways from the Zolgensma Pricing Stormalmost 7 years ago
FDA Faces ‘Explosion’ in Growth of Gene Therapiesalmost 7 years ago
Mapping Out the Future of Cell and Gene Therapyalmost 7 years ago
High-Stakes Manufacturing: Mitigating the Risksalmost 7 years ago
Gene Therapy: How ‘Advanced’ is Europe?almost 7 years ago
Luxturna: A Vision for Curative Therapy AccessAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
What Kinds of Disruption are GLP-1s Expected to Face
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
The Evolving Relationship Between FDA and Biotech
5